1. A packaged dosage form of a stable solid pharmaceutical composition containing amlodipine base or its pharmaceutically acceptable salts and bisoprolol fumarate and pharmaceutically acceptable excipients, packaged in a moisture-proof package and additionally containing less than 0.5% by weight of the active ingredients of a compound of the formula where amlodipine base or its pharmaceutically acceptable salts and bisoprolol fumarate are not separated in the composition. 2. A dosage form according to claim 1, characterized in that the composition contains amlodipine besilate from among the pharmaceutically acceptable salts of amlodipine. A dosage form according to claim 1, characterized in that the composition contains less than 0.3% of the compound of formula (3). 4. A dosage form according to claim 1, characterized in that the composition contains less than 0.2% of the compound of formula (3) .5. The dosage form according to claim 1, characterized in that the composition is packaged in a cold forming blister pack (the so-called cold forming blister pack / CFF /) of an OPA / AL / PVC composite foil (oriented polyamide / aluminum / polyvinyl chloride foil) coated with aluminum membrane foil. 6. A dosage form according to claim 1, characterized in that the composition is packaged in a blister pack of a thermoformable moisture-proof composite foil and coated with an aluminum membrane foil. A dosage form according to claim 1, characterized in that the composition is packaged in a glass or polypropylene container equipped with a sealed lid for a container of polyethylene or polypropylene. Dosage form according to any one of paragraphs. 1-7, which is a tablet or to1. Упакованная лекарственная форма стабильной твердой фармацевтической композиции, содержащей основание амлодипина или его фармацевтически приемлемые соли и бисопролола фумарат и фармацевтически приемлемые эксципиенты, упакованная во влагонепроницаемую упаковку и дополнительно содержащая меньше чем 0,5% от мас
